Vanguard Personalized Indexing Management LLC Buys 11,448 Shares of Organon & Co. $OGN

Vanguard Personalized Indexing Management LLC grew its stake in shares of Organon & Co. (NYSE:OGN) by 14.1% in the second quarter, HoldingsChannel.com reports. The fund owned 92,893 shares of the company’s stock after acquiring an additional 11,448 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Organon & Co. were worth $899,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of OGN. Hanson & Doremus Investment Management bought a new stake in shares of Organon & Co. during the 2nd quarter valued at $26,000. Ransom Advisory Ltd bought a new stake in shares of Organon & Co. during the 1st quarter worth $32,000. Brooklyn Investment Group lifted its position in shares of Organon & Co. by 1,012.3% during the 1st quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock worth $46,000 after buying an additional 2,794 shares during the last quarter. Ridgewood Investments LLC bought a new stake in shares of Organon & Co. during the 2nd quarter worth $48,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Organon & Co. during the 1st quarter worth $51,000. 77.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Organon & Co. currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

Organon & Co. Price Performance

Organon & Co. stock opened at $9.28 on Monday. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The company has a market capitalization of $2.41 billion, a PE ratio of 3.45, a P/E/G ratio of 0.84 and a beta of 0.63. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.05. The stock has a 50-day moving average price of $9.93 and a two-hundred day moving average price of $9.99.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.94 by $0.06. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the company earned $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. Analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were given a $0.02 dividend. The ex-dividend date was Friday, August 15th. This represents a $0.08 annualized dividend and a yield of 0.9%. Organon & Co.’s dividend payout ratio (DPR) is currently 2.97%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.